vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $220.8M, roughly 1.1× UNIVERSAL TECHNICAL INSTITUTE INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 5.8%, a 5.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-19.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 9.5%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
ANIP vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $220.8M |
| Net Profit | $27.5M | $12.8M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 7.1% |
| Net Margin | 11.1% | 5.8% |
| Revenue YoY | 29.6% | 9.6% |
| Net Profit YoY | 367.5% | -42.1% |
| EPS (diluted) | $1.14 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $220.8M | ||
| Q3 25 | $227.8M | $222.4M | ||
| Q2 25 | $211.4M | $204.3M | ||
| Q1 25 | $197.1M | $207.4M | ||
| Q4 24 | $190.6M | $201.4M | ||
| Q3 24 | $148.3M | $196.4M | ||
| Q2 24 | $138.0M | $177.5M | ||
| Q1 24 | $137.4M | $184.2M |
| Q4 25 | $27.5M | $12.8M | ||
| Q3 25 | $26.6M | $18.8M | ||
| Q2 25 | $8.5M | $10.7M | ||
| Q1 25 | $15.7M | $11.4M | ||
| Q4 24 | $-10.3M | $22.2M | ||
| Q3 24 | $-24.2M | $18.8M | ||
| Q2 24 | $-2.3M | $5.0M | ||
| Q1 24 | $18.2M | $7.8M |
| Q4 25 | 14.1% | 7.1% | ||
| Q3 25 | 15.9% | 11.2% | ||
| Q2 25 | 6.6% | 6.9% | ||
| Q1 25 | 13.3% | 8.1% | ||
| Q4 24 | -2.3% | 13.6% | ||
| Q3 24 | -13.8% | 13.3% | ||
| Q2 24 | 3.7% | 4.2% | ||
| Q1 24 | 14.8% | 6.1% |
| Q4 25 | 11.1% | 5.8% | ||
| Q3 25 | 11.7% | 8.4% | ||
| Q2 25 | 4.0% | 5.2% | ||
| Q1 25 | 8.0% | 5.5% | ||
| Q4 24 | -5.4% | 11.0% | ||
| Q3 24 | -16.3% | 9.6% | ||
| Q2 24 | -1.7% | 2.8% | ||
| Q1 24 | 13.2% | 4.2% |
| Q4 25 | $1.14 | $0.23 | ||
| Q3 25 | $1.13 | $0.33 | ||
| Q2 25 | $0.36 | $0.19 | ||
| Q1 25 | $0.69 | $0.21 | ||
| Q4 24 | $-0.45 | $0.40 | ||
| Q3 24 | $-1.27 | $0.35 | ||
| Q2 24 | $-0.14 | $0.09 | ||
| Q1 24 | $0.82 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $162.8M |
| Total DebtLower is stronger | — | $101.4M |
| Stockholders' EquityBook value | $540.7M | $335.9M |
| Total Assets | $1.4B | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $162.8M | ||
| Q3 25 | $262.6M | $169.1M | ||
| Q2 25 | $217.8M | $70.7M | ||
| Q1 25 | $149.8M | $96.0M | ||
| Q4 24 | $144.9M | $172.0M | ||
| Q3 24 | $145.0M | $161.9M | ||
| Q2 24 | $240.1M | $115.5M | ||
| Q1 24 | $228.6M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $540.7M | $335.9M | ||
| Q3 25 | $505.8M | $328.1M | ||
| Q2 25 | $436.8M | $306.8M | ||
| Q1 25 | $418.6M | $293.9M | ||
| Q4 24 | $403.7M | $280.0M | ||
| Q3 24 | $405.9M | $260.2M | ||
| Q2 24 | $455.8M | $239.4M | ||
| Q1 24 | $452.0M | $232.6M |
| Q4 25 | $1.4B | $834.0M | ||
| Q3 25 | $1.4B | $826.1M | ||
| Q2 25 | $1.3B | $740.8M | ||
| Q1 25 | $1.3B | $720.4M | ||
| Q4 24 | $1.3B | $753.8M | ||
| Q3 24 | $1.3B | $744.6M | ||
| Q2 24 | $920.8M | $706.0M | ||
| Q1 24 | $914.5M | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $3.1M |
| Free Cash FlowOCF − Capex | $29.1M | $-19.2M |
| FCF MarginFCF / Revenue | 11.8% | -8.7% |
| Capex IntensityCapex / Revenue | 0.5% | 10.1% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $3.1M | ||
| Q3 25 | $44.1M | $57.1M | ||
| Q2 25 | $75.8M | $18.1M | ||
| Q1 25 | $35.0M | $-789.0K | ||
| Q4 24 | $15.9M | $23.0M | ||
| Q3 24 | $12.5M | $67.5M | ||
| Q2 24 | $17.4M | $10.0M | ||
| Q1 24 | $18.3M | $-2.5M |
| Q4 25 | $29.1M | $-19.2M | ||
| Q3 25 | $38.0M | $40.6M | ||
| Q2 25 | $71.8M | $6.8M | ||
| Q1 25 | $32.5M | $-11.7M | ||
| Q4 24 | $13.5M | $19.6M | ||
| Q3 24 | $7.7M | $60.0M | ||
| Q2 24 | $13.0M | $3.0M | ||
| Q1 24 | $13.7M | $-8.4M |
| Q4 25 | 11.8% | -8.7% | ||
| Q3 25 | 16.7% | 18.3% | ||
| Q2 25 | 34.0% | 3.4% | ||
| Q1 25 | 16.5% | -5.7% | ||
| Q4 24 | 7.1% | 9.7% | ||
| Q3 24 | 5.2% | 30.6% | ||
| Q2 24 | 9.4% | 1.7% | ||
| Q1 24 | 10.0% | -4.6% |
| Q4 25 | 0.5% | 10.1% | ||
| Q3 25 | 2.7% | 7.4% | ||
| Q2 25 | 1.9% | 5.5% | ||
| Q1 25 | 1.3% | 5.3% | ||
| Q4 24 | 1.3% | 1.7% | ||
| Q3 24 | 3.2% | 3.8% | ||
| Q2 24 | 3.2% | 4.0% | ||
| Q1 24 | 3.3% | 3.2% |
| Q4 25 | 1.10× | 0.24× | ||
| Q3 25 | 1.66× | 3.04× | ||
| Q2 25 | 8.87× | 1.69× | ||
| Q1 25 | 2.23× | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | 1.00× | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
